Scientist/Senior Scientist – Oligonucleotides ADME/PK & Bioanalytics

The RNA Society; Indiana (PA); On-site; USD 141,000 - 203,000; Full time

Job summary

NATi is seeking a Scientist/Senior Scientist to lead ADME, PK, biodistribution, and bioanalytical strategies for oligonucleotide therapeutics. The role focuses on advancing programs from discovery to IND-enabling studies, integrating PK/PD data and translational modeling to inform candidate selection, and driving cross-functional collaboration in a fast-paced startup environment.

The candidate will design and execute PK studies across rodent and non-rodent models, develop robust bioanalytical

Qualifications

• PhD in Pharmacokinetics, Pharmaceutical Sciences, Molecular Biology, or related field.
• Hands-on experience with oligonucleotide therapeutics in preclinical development is required.
• Demonstrated expertise in PK study design, biodistribution, and bioanalytical platforms (qPCR, LC-MS/MS, hybridization assays).
• Experience leading in vivo evaluation of targeted oligonucleotides (e.g., AOCs) for extrahepatic delivery.

Responsibilities

• Lead ADME, PK, biodistribution and bioanalytical strategies for oligonucleotide therapeutics.
• Design, execute, and interpret PK studies in rodent and non-rodent models.
• Develop and validate assays for oligonucleotide quantification in plasma and tissues.
• Integrate PK/PD and biodistribution data to inform candidate selection and translational modeling.
• Lead external CRO studies and ensure scientific quality and timelines.

Skills

Analytical thinking

Data-driven decisions

Cross-functional collaboration

Education

PhD in Pharmacokinetics or related field

Tools

qPCR

LC-MS/MS

Hybridization assays

Job description

Position Overview

We are seeking a highly motivated Scientist/Senior Scientist to lead and support ADME, pharmacokinetics (PK), biodistribution, and bioanalytical strategy for oligonucleotide therapeutics. This role will be central in advancing programs from discovery through preclinical development by enabling quantitative understanding of exposure, tissue distribution, target engagement, and PK/PD relationships. The successful candidate will lead the design and execution of preclinical DMPK strategies, integrate PK/PD and biodistribution data to inform candidate selection, and drive translational strategy to support IND-enabling studies. This position requires deep expertise in oligonucleotide PK, rigorous analytical thinking, and the ability to operate effectively in a fast-paced, cross-functional startup environment.

Key Responsibilities

• ADME, Pharmacokinetics & Translational Strategy
• Design, execute, and interpret PK studies for different oligonucleotides in rodent and non-rodent models.
• Characterize absorption, tissue distribution, metabolism, and excretion (ADME) of oligonucleotides with emphasis on both hepatic and extrahepatic tissue exposure (e.g., muscle, adipose tissue) where relevant; Establish in vitro and/or ex vivo assays to assess molecule’s stability, protein binding, and metabolite profiling as needed.
• Link molecule exposure (PK) to pharmacodynamic (PD) effects (e.g., target knockdown, steric blocking, pharmacological response)
• Design and interpret single- and repeat-dose PK studies to support dose selection, regimen optimization, and translational modelling.
• Lead and be accountable for preclinical proof-of-concept (POC) for targeted oligonucleotide platforms (e.g., antibody-oligonucleotide conjugates/AOCs) for extrahepatic delivery (e.g., muscle, adipose tissue)
• Bioanalytical Strategy
• Develop, validate, and implement robust bioanalytical assays for oligonucleotide quantification in plasma and tissues (e.g., qPCR-based assays, SL-RT-PCR, Hybridization ELISA, LC-MS/MS)
• Ensure assays are fit-for-purpose with appropriate sensitivity, specificity, and dynamic range, particularly for low-abundance tissues
• Support biomarker strategies (e.g., target mRNA knockdown, protein modulation).
• Ensure regulatory alignment (GLP where applicable).
• Cross-functional & Project Leadership
• Provide scientific and project leadership for ADME/PK components of oligonucleotide programs, particularly those focused on extrahepatic delivery
• Partner closely with discovery biology/, oligonucleotide chemistry, and bioconjugation scientists.
• Contribute to IND-enabling studies and regulatory documentation.
• Oversee external CRO studies, ensuring scientific quality, timelines, and strategic alignment

Qualifications & Experience

• PhD in Pharmacokinetics, Pharmaceutical Sciences, Molecular Biology, or related field.
• A minimum of +4 (Scientist) or +8 (Senior Scientist) years of hands-on experience in preclinical development of oligonucleotide therapeutics
• Demonstrated expertise in PK study design and analysis, Tissue biodistribution, including extrahepatic tissues, and Bioanalytical platforms (qPCR, LC-MS/MS, hybridization assays)
• Hands-on experience leading or contributing to in vivo evaluation of targeted oligonucleotides (e.g., AOCs) with demonstrated success in POC for extrahepatic delivery (e.g., Skeletal muscle, adipose tissue)
• Experience integrating biodistribution, PK/PD, and functional outcomesto drive candidate selection
• Experience working in metabolic disease models is highly desirable
• Demonstrated experience in project leadership or scientific ownership within cross-functional teams
• Experience establishing capabilities and working with CRO partners
• Strong analytical rigor and data-driven decision-making
• Effective communicator with the ability to influence cross-functional stakeholders
• This position is based in Singapore. Successful candidates must be willing to relocate to Singapore.

Global Recruitment & Notes

NATi is conducting a global search for top-tier talent in RNA therapeutics. We welcome applications from leading pharmaceuticals scientists and biotech innovators worldwide. This role provides a highly competitive compensation package aligned with global industry standards, including attractive benefits and long-term career growth opportunities within Singapore’s thriving biomedical innovation ecosystem. Join us in shaping the future of RNA-based medicines and establishing Singapore as a world-class hub for nucleic acid therapeutics.